バイオマテリアルの世界市場-2025～2033年

バイオマテリアルの世界市場は、2023年に1,773億米ドルに達し、2033年には3,999億米ドルに達すると予測され、予測期間2025～2033年のCAGRは10.7%で成長する見込みです。

バイオマテリアルは医療に不可欠であり、傷害や疾病後の機能を回復し治癒を促進します。天然または合成のものがあり、損傷した組織や生物学的機能をサポート、強化、代替するために使用されます。バイオマテリアルの分野は、医学、生物学、物理学、化学、組織工学を組み合わせたものであり、最近では再生医療や組織工学における発見もあります。この分野は過去10年で大きく成長しました。

市場力学：

促進要因と阻害要因

慢性疾患の増加

世界のバイオマテリアル市場は、心血管疾患、糖尿病、関節炎、がんなどの慢性疾患の有病率の増加により拡大しています。これらの疾患には、インプラント、人工関節、ステント、ドラッグデリバリーシステムなどの高度な医療介入が必要であり、機能性と安全性においてバイオマテリアルに大きく依存しています。金属やポリマーベースのバイオマテリアルは、整形外科用インプラントやドラッグデリバリーシステムにおいて極めて重要です。生体適合性と耐久性のある材料への需要は、これらの状態を管理するための長期的なソリューションの必要性によって増加しています。慢性疾患が世界のヘルスケアシステムに負担をかける中、患者の予後を改善し、革新的な治療を可能にするバイオマテリアルの役割は拡大し続けています。

例えば、National Center for Chronic Disease Prevention and Health Promotionによると、米国では心臓病、がん、糖尿病、肥満、高血圧など、少なくとも1つの主要な慢性疾患を持つ人が1,290億人います。米国の主要死因トップ10のうち5つが、予防・治療可能な慢性疾患に関連しています。過去20年間、有病率は着実に増加しており、この傾向は今後も続くと予想されます。複数の慢性疾患を抱えるアメリカ人の割合は増加しており、42％が2つ以上、12％が少なくとも5つの慢性疾患を抱えています。慢性疾患は米国のヘルスケアシステムにも大きな影響を与えており、年間4兆1,000億米ドルの支出の90％を占めています。

したがって、バイオマテリアルは、このような病態を効果的に管理・治療するために設計されたインプラント、補綴物、ドラッグデリバリーシステムの開発に不可欠であり、これらのニーズに対応する上で重要な役割を担っています。

バイオマテリアルに関連する合併症のリスク

世界のバイオマテリアル市場は、バイオマテリアル関連の合併症のリスクという大きな課題に直面しています。これらの合併症は、不適切な材料選択、最適とは言えない製造工程、または患者固有の要因によって発生する可能性があります。インプラントやデバイスの不具合は、追加のヘルスケアコスト、治療期間の延長、修正手術につながる可能性があります。このような合併症は、バイオマテリアルをベースとしたソリューションの有効性を損ない、患者の転帰に影響を及ぼす可能性があるため、これらの製品に対する信頼を低下させます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 慢性疾患の罹患率の上昇
  • 抑制要因
    • バイオマテリアル関連の合併症のリスク
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 製品タイプ別

• 金属バイオマテリアル
• ポリマーバイオマテリアル
• セラミックバイオマテリアル
• 天然バイオマテリアル
• 複合バイオマテリアル

第7章 用途別

• 心臓血管
• 整形外科
• 歯科
• 眼科
• 外傷治癒
• 神経学
• その他

第8章 エンドユーザー別

• 病院
• 専門クリニック
• 外来手術センター
• 学術研究機関
• バイオテクノロジー企業

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• BASF SE
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Evonik Industries AG
• Royal DSM N.V.
• Corbion N.V.
• Zimmer Biomet Holdings, Inc.
• Medtronic plc
• Stryker Corporation
• Johnson & Johnson（DePuy Synthes）
• Smith & Nephew plc
• Wright Medical Group N.V.

第12章 付録

The global biomaterials market reached US$ 177.3 billion in 2023 and is expected to reach US$ 399.9 billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033.

Biomaterials are essential in medicine, restoring function and facilitating healing after injury or disease. They can be natural or synthetic and are used to support, enhance, or replace damaged tissue or biological functions. The field of biomaterials combines medicine, biology, physics, chemistry, and tissue engineering, with recent discoveries in regenerative medicine and tissue engineering. The field has grown significantly in the past decade.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Chronic Diseases

The global biomaterials market is growing due to the increasing prevalence of chronic diseases like cardiovascular diseases, diabetes, arthritis, and cancer. These diseases require advanced medical interventions like implants, prosthetics, stents, and drug delivery systems, which rely heavily on biomaterials for functionality and safety. Metallic and polymer-based biomaterials are crucial in orthopedic implants and drug delivery systems. The demand for biocompatible and durable materials is accelerated by the need for long-term solutions to manage these conditions. As chronic diseases strain healthcare systems globally, biomaterials' role in enhancing patient outcomes and enabling innovative treatments continues to expand.

For instance, according to National Center for Chronic Disease Prevention and Health Promotion the US has 129 Billion people with at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. Five of the top 10 leading causes of death in the US are associated with preventable and treatable chronic diseases. Over the past two decades, prevalence has steadily increased, and this trend is expected to continue. An increasing proportion of Americans are dealing with multiple chronic conditions, with 42% having two or more and 12% having at least five. Chronic diseases also significantly impact the US healthcare system, accounting for 90% of annual $4.1 trillion expenditure.

Hence, biomaterials play a vital role in addressing these needs, as they are integral to developing implants, prosthetics, and drug delivery systems designed to manage and treat these conditions effectively.

Risk of Biomaterial-related Complications

The global biomaterials market faces a significant challenge due to the risk of biomaterial-related complications. These complications can occur due to improper material selection, suboptimal manufacturing processes, or patient-specific factors. The failure of implants or devices can lead to additional healthcare costs, extended treatments, and corrective surgeries. These complications can undermine the effectiveness of biomaterial-based solutions and affect patient outcomes, reducing confidence in these products.

Segment Analysis

The global biomaterials market is segmented based on product type, application, end user and region.

Product Type:

Metallic Biomaterials segment is expected to dominate the biomaterials market share

The metallic biomaterials segment holds a major portion of the biomaterials market share and is expected to continue to hold a significant portion of the biomaterials market share during the forecast period.

Metallic biomaterials, primarily made of stainless steel, titanium, and cobalt-chromium alloys, are essential in the global biomaterials market due to their excellent mechanical properties, durability, and biocompatibility. They are commonly used in orthopedic implants, dental implants, cardiovascular stents, and surgical instruments, particularly in load-bearing implants like joint replacements and bone fracture fixation.

Moreover, the demand for metallic biomaterials is growing due to the aging population and increasing prevalence of chronic conditions like arthritis, cardiovascular diseases, and osteoporosis. Advances in surface modification techniques, such as coating metallic biomaterials with biocompatible materials, are driving their use in more complex medical procedures. As these materials evolve, their role in the biomaterials market remains vital for improving healthcare outcomes and patient quality of life.

Application:

Cardiovascular segment is the fastest-growing segment in biomaterials market share

The cardiovascular segment is the fastest-growing segment in the biomaterials market share and is expected to hold the market share over the forecast period.

Cardiovascular segment plays important role in biomaterials as they are crucial in the development of various cardiovascular devices, such as stents, heart valves, pacemakers, and vascular grafts. Metallic biomaterials like titanium and stainless steel are used in stents and pacemakers due to their strength and corrosion resistance. Polymer-based biomaterials are used in heart valve replacements and vascular grafts due to their flexibility and better integration with biological tissues. The demand for biomaterial-based solutions is increasing due to cardiovascular diseases being a leading cause of mortality worldwide. The market for biomaterials in cardiovascular applications is expected to expand due to ongoing advancements in material science and technology.

For instance, in January 2023, Scientists at the University of California have developed a new iomaterial that can be injected intravenously, reduce inflammation, and repair cardiac tissue damage from heart attacks. The biomaterial was tested in a rodent model and proved effective in treating tissue damage caused by heart attacks in both rodent and large animal models. The study suggests the iomaterial could be beneficial for patients with traumatic brain injury and pulmonary arterial hypertension.

Geographical Analysis

North America is expected to hold a significant position in the bomaterials market share

North America holds a substantial position in the biomaterials market and is expected to hold most of the market share due to the its advanced healthcare infrastructure, high healthcare expenditure, and robust medical device industry. The region's focus on research and development, particularly in tissue engineering and regenerative medicine, has led to innovation in biomaterials. The US, particularly the US, is home to leading companies specializing in biomaterial technologies and medical devices, contributing to market growth. The increasing prevalence of chronic diseases and the aging population in North America further amplify the demand for biomaterial-based solutions. High healthcare spending and regulatory support further strengthen the market, making North America a dominant force in the global biomaterials market.

For instance, in January 2024, Xenco Medical showcased its TrabeculeX Continuum at the 2024 Consumer Electronics Show. This technology bridges Digital Health and Biomaterials, combining the FDA-cleared TrabeculeX Bioactive Matrix and the TrabeculeX Recovery App. It unifies a patient's biomaterial implantation and postoperative journey, allowing surgeons to enroll patients in the Recovery App and engage in Remote Therapeutic Monitoring. The TrabeculeX Continuum is an unprecedented intersection of regenerative medicine and digital health.

Europe is growing at the fastest pace in the biomaterials market

Europe holds the fastest pace in the biomaterials market and is expected to hold most of the market share due to the strong healthcare system, growing elderly population, and significant investments in research and innovation. The EU and other countries have established regulations promoting advanced biomaterials, leading to a flourishing medical device industry. Biomaterials are crucial in producing implants, prosthetics, and surgical instruments. The aging population in Europe is a significant driver, as they often experience chronic diseases like cardiovascular disease, osteoarthritis, and diabetes. Europe's leading research institutions and universities focus on biomaterial science, encouraging continuous innovation in materials like bioresorbable stents, tissue-engineered scaffolds, and orthopedic implants.

For instance, in July 2024, UK-based Biotech 4D Medicine has raised £3.4m in a Series A round, led by Oshen Holdings and supported by DSW Ventures, SFC Capital, Boundary Capital, and private investors. The funding will enable the company to complete pre-clinical testing of its first product range and seek FDA clearance for entry into the US market. 4D Medicine, a spin-out from the Universities of Birmingham and Warwick, develops a resorbable biomaterial called 4Degra for implants and soft tissue scaffolds. Preliminary testing shows the biomaterial gradually erodes and is resorbed by normal metabolic processes as natural tissue grows.

Competitive Landscape

The major global players in the biomaterials market include BASF SE, Evonik Industries AG, Royal DSM N.V., Corbion N.V., Zimmer Biomet Holdings, Inc, Medtronic plc, Stryker Corporation, Johnson & Johnson (DePuy Synthes), Smith & Nephew plc, Wright Medical Group N.V. and among others.

Key Developments

• In October 2023, The University of Birmingham Enterprise has launched the Birmingham Dental and Biomaterials Testing Service (BiMaTs), a consultancy and comprehensive materials testing service for dental and biomaterial manufacturers. Co-founded by Professor Josette Camilleri and Professor Will Palin, BiMaTs will assess the mechanical and physical properties of materials and the biological properties of material-tissue interfaces, developing tailored protocols for individual clients.

Emerging Players

The emerging players in the biomaterials market include Nexeon MedSystems, NuVasive, Inc, Amastan Technologies, Matexcel, Regenovo Biotechnology Co., Ltd., Bioretec Ltd., Aspect Biosyst and among others and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global biomaterials market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Chronic Diseases
  • 4.1.2. Restraints
    • 4.1.2.1. Risk of Biomaterial-related Complications
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Metallic Biomaterials*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Polymeric Biomaterials
• 6.4. Ceramic Biomaterials
• 6.5. Natural Biomaterials
• 6.6. Composite Biomaterials

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Cardiovascular*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Orthopedic
• 7.4. Dental
• 7.5. Ophthalmology
• 7.6. Wound Healing
• 7.7. Neurology
• 7.8. Others

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty Clinics
• 8.4. Ambulatory Surgical Centers
• 8.5. Academic and Research Institutes
• 8.6. Biotechnology Companies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. BASF SE *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Evonik Industries AG
• 11.3. Royal DSM N.V.
• 11.4. Corbion N.V.
• 11.5. Zimmer Biomet Holdings, Inc.
• 11.6. Medtronic plc
• 11.7. Stryker Corporation
• 11.8. Johnson & Johnson (DePuy Synthes)
• 11.9. Smith & Nephew plc
• 11.10. Wright Medical Group N.V.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1 About Us and Services
• 12.2 Contact Us